Drug trial for hard-to-control focal epilepsy with brain scar
Treatments studied
Part of Brain & nervous system clinical trials.
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 70 years old and have epilepsy that still isn’t controlled after trying at least 2 appropriate seizure medicines at adequate doses.
- Your seizures are the right type: focal cortical dysplasia (FCD) type I or II confirmed by recent imaging or past surgery pathology review.
- During the 6-week baseline diary period, you had at least 4 countable seizures, with no more than 21 days completely seizure-free.
- You can safely follow study rules: read/understand consent (or a legal representative can), keep seizure diaries, swallow capsules whole, and attend visits on schedule.
- You can’t change your seizure medicine plan during the screening and early study periods; it must be stable for the required time.
- You must use reliable birth control if you could get pregnant, or if you have a partner who could get pregnant, for the full time window around dosing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at ways to diagnose and treat focal epilepsy that isn't controlled by medications. It includes patients with or without a visible brain lesion on imaging.
This study tests an investigational drug called AV078 for people with tuberous sclerosis complex (TSC) whose seizures are not controlled by at least two current medications. The goal is to see if AV078 can reduce seizure frequency safely, and participants continue their usual seizure medications during the trial.
This trial tests a new type of stimulation placed under the skin to help control seizures in people with epilepsy. It is for patients whose seizures are not controlled with medication and who cannot have surgery.
This trial is testing a new treatment made from human stem cells to see if it is safe and helpful for people whose seizures are not controlled by current medications. If you have drug-resistant epilepsy, this treatment might offer a new option.
This study tests a personalized, non-invasive brain stimulation method called tDCS for people with drug-resistant epilepsy that starts in one part of the brain. It aims to reduce seizures in those who cannot have surgery or have not been helped by surgery.
This study tests whether a new medication called RAP-219 can help adults with focal seizures (seizures that start in one area of the brain) control their seizures better. You would take this medication alongside your current seizure drugs for about 12 weeks.
Hear when a new Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.